Stem Cell Agency Invests Almost $20 Million in Clinical Trial for Deadly Brain Cancer

Newswise — San Francisco, CA – Glioblastoma is the most common and the most aggressive form of brain tumor, so funding an equally aggressive approach to treating it was a no-brainer for CIRM, California’s stem cell agency. The agency’s governing …

[Read the full article here]

Comments are closed.